Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1,N4-substituted 3,5-dinitro sulfanilamide, GB-II-150

Life Sciences

Volumn 79, Issue 11, 2006, Pages 1081-1093

  Wu, Di ^a   George, Tesmol G ^a   Hurh, Eunju ^a   Werbovetz, Karl A ^a   Dalton, James T ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Metabolism; Pharmacokinetics; Sulfanilamide

Indexed keywords

GB II 150; N1 PHENYL 3,5 DINITRO N4,N4 DIBUTYLSULFANILAMIDE; NITROREDUCTASE; SULFANILAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; FLAGELLATE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEISHMANIA DONOVANI; LIVER; MALE; NONHUMAN; OXIDATION; RAT; RAT STRAIN; SUBSTITUTION REACTION; TRYPANOSOMA; TRYPANOSOMA BRUCEI;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; BIOLOGICAL AVAILABILITY; KINETOPLASTIDA; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFANILAMIDES; TUBULIN;

LEISHMANIA DONOVANI; TRYPANOSOMA BRUCEI;

EID: 33745989190     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.03.028     Document Type: Article

References (13)

1. 4-substituted 3,5-dinitro sulfanilamides against African trypanosomes and Leishmania. Journal of Medicinal Chemistry 47 (2004) 1823-1832
2. Croft S., Barrett M., and Urbina J. Chemothrapy of trypanosomiases and leishmaniasis. Trends in Parasitology 21 (2005) 508-512
3. Davies B., and Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10 (1993) 1093-1095
4. Grundy J.S., Eliot L.A., and Foster R.T. Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharmaceutics and Drug Disposition 18 6 (1997) 509-522
5. Fairlamb A.H. Chemotherapy of human African trypanosomiasis: current and future prospects. Trends in Parasitology 19 (2003) 488-494
6. Lambert J.B., Shurvell H.F., Lightner D.A., and Cooks R.G. Fragmentation and ion chemistry. In: Challice J. (Ed). Organic Structural Spectroscopy (1998), Prentice Hall, Upper Saddle River, NY 392-437
7. McLafferty F.W. Mass spectra of common compound classes. Interpretation of Mass Spectra. 4th ed. (1993), University Science Books, Sausalito, CA 226-239
8. Nemes K.B., Abermann M., Bojti E., Grezal G., Al-Behaisi S., and Klebovich I. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. Journal of Pharmacy and Pharmacology 52 1 (2000) 47-51
9. In: Ryan K.J., and Ray C.G. (Eds). Flagellates. In Sherris Medical Microbiology-An Introduction to Infectious Diseases (2004), McGraw-Hill, New York 749-761
10. n Application Report No. 305.
11. Werbovetz K.A. Promising therapeutic targets for antileishmanial drugs. Expert Opinion on Therapeutic Targets 6 (2002) 407-422
12. Werbovetz K.A., Sackett D.L., Delfin D., Bhattacharya G., Salem M., Obrzut T., Rattendi D., and Bacchi C. Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4, N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites. Molecular Pharmacology 64 (2003) 1325-1333
13. Wu Z., Gao W., Phelps M.A., Wu D., Miller D.D., and Dalton J.T. Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Analytical Chemistry 76 (2004) 839-847